Law360, New York (August 18, 2009) -- A federal judge has ruled that one of Eli Lilly & Co.'s patents for cancer treatment Gemzar is invalid, in a dispute with Sun Pharmaceutical Industries Ltd. over a proposed generic version of the drug.
Judge George Caram Steeh of the U.S. District Court for the Eastern District of Michigan on Monday deemed U.S. Patent Number 5,464,826, a method patent, invalid for obviousness-type double patenting....
